Semax's Unproven Role in Migraine Treatment Raises Concerns
Semax, a synthetic peptide developed in Russia, is being explored by some as a potential treatment for migraines, despite lacking FDA approval or clinical trial evidence for this use. Originally studied for stroke recovery and cognitive enhancement, Semax has gained attention in biohacking communities for its purported neuroprotective and anti-inflammatory properties. However, these claims are largely anecdotal, with no peer-reviewed research supporting its efficacy in treating migraines. In the U.S., Semax is available only as a research chemical, raising concerns about dosing accuracy and product purity. 
